| Tapering with pharmaceutical gamma-hydroxybutyric acid (GHB) led to a milder withdrawal syndrome than tapering with benzodiazepines in patients with GHB use disorder during detoxification. |
| Patients with GHB use disorder had a one in five chance of developing delirium during detoxification when tapering with benzodiazepines, compared with 1 in 40 when tapering with pharmaceutical GHB. |
| There were no differences in GHB craving levels during detoxification between patients with GHB use disorder receiving pharmaceutical GHB tapering or benzodiazepine tapering. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.